Compare AstraZeneca plc (AZN) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.63. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and iShares iBoxx $ High Yield Corporate Bond ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | HYG | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $81.32 |
52-Week Low | $147.06 | $78.72 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.63 with minimal daily movement (+0.19%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights investor rotation into fixed income ETFs amid rising yields, though specific articles question HYG's competitiveness versus peers on expenses and performance.
The outlook for HYG is clouded by bearish technicals and mixed sentiment. Opportunities exist from high-yield demand, but risks include rising interest rates, inflation fears, and underperformance versus alternatives. Investors should weigh the ETF's 6.5% yield against potential downside from economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
